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Background:  Heart failure (HF) is a major cause of morbidity and mortality in western societies. This dilemma reflects a lack of innovative 
therapies targeting the underlying root causes of the disease. A key underpinning of HF is the depletion of S100A1 in cardiomyocytes, which 
results in abnormal intracellular calcium (Ca2+) cycling and poor contractility. As a prerequisite to clinical application, we sought to determine 
therapeutic effectiveness and safety of S100A1 gene therapy using adeno-associated viral serotype 9 (AAV9) in a preclinical large animal HF model 
recapitulating the human HF phenotype.
Methods and Results:  HF in domestic pigs was induced by ballon-occlusion of the left circumflex coronary artery (LCx) resulting in myocardial 
infarction (MI). 2 weeks post-MI, when infarcted animals (n=32) displayed significant left ventricular (LV) contractile dysfunction compared to 
sham-operated (n=13) animals, retrograde coronary venous delivery of AAV9-S100A1 (1.5x1013 viral particles, n=9) to LV non-infarcted remote 
myocardium was performed while AAV9-luciferase (AAV9-luc, n=9) and saline (n=14) treatment served as control. At 14 weeks post-MI, both 
HF-control groups showed significantly decreased myocardial S100A1 protein along with progressive deterioration of cardiac performance, LV 
hypertrophy and sympathetic activation. In contrast, AAV9-S100A1 treated HF swine exhibited enhanced cardiac S100A1 protein levels resulting in 
significantly improved cardiac performance, reversed LV remodeling, improved inotropic reserve in response to dobutamine and restored cardiac 
energetics at whole heart and isolated cardiomyocyte level. Cardiac-restricted transgene expression and uncompromised extra-cardiac organ 
function indicated a favorable safety profile.
Conclusions:  Our translational study shows long-term therapeutic effectiveness and a favorable safety profile of AAV9-S100A1 gene therapy in 
a preclinical HF model emanating from the unique molecular profile of S100A1. Employing cardiac-targeted gene delivery techniques and a gene 
dosage directly applicable to humans, these results pave the way for clinical application of S100A1 gene therapy in human HF.
